Comparison of Different First-Line Systemic Therapies in Advanced Biliary Tract Cancer Based on Updated Random Controlled Trials: A Systematic Review and Network Meta-Analysis

Table 5

Surface under the cumulative ranking curve values for progression-free survival.

Treatment	SUCRA
GemOxa+Erlotinib	91.2
GemCis+Durvalumab	82.7
GemOxa+Panitumumab	81.2
GemOxa+Cetuximab	79
XELOX	76
GemOxa	69.5
GemCis+Cediranib	66
GemCis+Merestinib	64.2
GemS1	63.7
GemCis	51.9
S1Cis	50.5
GemCis+Ramucirumab	49
FOLFIRINOX	37.1
S1	22.5
Gem	21.6
FUFA	13.9
Gem+Vandetanib	13.3
Vandetanib	10.5
BSC	6.2

GemCis: gemcitabine plus cisplatin; GemOxa: gemcitabine plus oxaliplatin; GemS1: gemcitabine plus S-1; S1Cis: S1 plus cisplatin; XELOX: capecitabine plus oxaliplatin; BSC: best supportive care; FUFA: fluorouracil+folinic; FOLFIRINOX: oxaliplatin plus irinotecan plus infusional fluorouracil.